Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Background Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like
ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited
treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Marine natural products are potent and promising sources of drugs among other natural
products of plant, animal, and microbial origin. To date, 20 drugs from marine sources are in …

Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse
primary sites that lack effective treatments. Using chemical genetic screens, we identified …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …